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Abstract: Irritable bowel syndrome (IBS) is a disorder of the brain-gut axis; the pathophysiological
mechanisms include altered colonic motility, bile acid metabolism, neurohormonal regulation,
immune dysfunction, alterations in the epithelial barrier and secretory properties of the gut.
This article reviews the mechanisms, efficacy, and safety of current pharmacotherapy, and medications
that are in phase III trials for the treatment of IBS. There remains a significant unmet need for effective
treatments—particularly for the pain component of IBS—although the introduction of drugs directed
at secretion, motility and a non-absorbable antibiotic provide options for the bowel dysfunction
in IBS.
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1. Introduction
Numerous pathophysiological mechanisms are implicated in IBS and it is likely that individual
or multiple disease processes in each individual patient lead to pain and diarrhoea, or pain and
constipation. As a result, IBS treatment is often selected on an individual basis, and is targeted at
the predominant or most troublesome symptom experienced by the patient, rather that attempting
to modify the disease and the natural history of the disorder [1]. This highlights the need for future
high-quality randomized controlled trials (RCTs) of interventions based on the pathophysiological
mechanisms, and the opportunity to confirm the presence of those mechanisms based on validated,
actionable biomarkers, such as abnormalities of colonic transit or bile acid metabolism [2,3].
Pharmacotherapy is one component of the treatment of IBS; other therapies can be considered either
alone or in association with pharmacotherapy and these include lifestyle changes, dietary modifications,
and psychological therapies, including relaxation and cognitive behavioral therapy.
An important component, and largely unmet need, in the treatment of IBS is pain. Sensory
neurons reach the central nervous system via vagal, thoracolumbar and lumbosacral pathways.
Parasympathetic afferents, comprising the majority of nerve fibers in the vagus and pelvic nerves,
convey non-conscious sensory information, to the nucleus of the solitary tract in the brainstem. Visceral
afferents course along sympathetic nerves, and convey painful stimuli to the spinal cord via the dorsal
roots. These afferents are equipped with a variety of pro- and antinociceptive ion channels and
receptors; the balance between pain sensing and suppressing signals finally determines the activation
status of the nerve ending [4]. Important neurotransmitters involved in visceral sensation are 5-HT
and neurokinins. Important channels mediating activation of afferent nerves are transient receptor
potential (TRP) ion channels, and TRPV1, TRPM8, and TRPA1 all act as molecular detectors of thermal
and chemical stimuli that activate sensory neurons to produce acute or persistent pain [5].
J. Clin. Med. 2017, 6, 101; doi:10.3390/jcm6110101 www.mdpi.com/journal/jcm
J. Clin. Med. 2017, 6, 101 2 of 16
Conventionally, IBS is divided into subtypes according to the predominant stool pattern because
this informs treatment options. Syntheses of the available literature have provided evidence-based
treatment recommendations for the management of IBS based on these symptom subtypes [6–9] based
on large high-quality trials, using Food and Drug Administration (FDA)-recommended endpoints to
judge efficacy. However, for many of the more traditional therapies, the RCTs studying these agents
were smaller, of lower quality, recruited heterogeneous groups of patients with IBS, and the endpoints
used were of debatable validity [10].
For each drug class, we summarize mechanism, efficacy and safety of IBS (Table 1).
Table 1. Summary of current treatments and drugs in development for IBS.
Therapy Mechanism ofAction Efficacy
Quality of
Data Adverse Events Limitations of Data
Antispasmodic
drugs
Smooth muscle
relaxation
May be
effective Low
More likely with antispasmodics in a
meta-analysis of 22 RCTs, particularly
dry mouth, dizziness, and
blurred vision
No high-quality trials,
heterogeneity between studies,
possible publication bias, and only
a small number of RCTs assessing
each individual antispasmodic
Peppermint oil Smooth musclerelaxation Effective Moderate
No increase in adverse events in a
meta-analysis of 4 RCTs Heterogeneity between studies
Antidepressants Central sensorymodulation Effective Moderate
More likely with antidepressants in a
meta-analysis of 17 RCTs, particularly
dry mouth and drowsiness
Few high-quality trials,
heterogeneity between studies,
possible publication bias, and
some atypical trials included
Ibodutant NeurokininNK2 antagonist
May be
effective Moderate
Promising visceral analgesic in a
phase 2B trial Awaiting phase 3 trials
Ebastine Histamine H1antagonist
May be
effective Low
Promising visceral analgesic in a
single center trial Awaiting phase 2B trials
TSPO inhibitor May beeffective Low
Modest efficacy in a single proof of
concept trial Awaiting phase 2B trials
Loperamide µ-opioidagonist Unknown Low Limited data
Few RCTs, with a small number of
participants, not all of whom
had IBS
Eluxadoline
Mixed opioid
receptor
modulator
Effective High.
Serious events included acute
pancreatitis and sphincter of Oddi
spasm. Nausea and headache
commoner with active therapy
Only a modest benefit over
placebo in published RCTs; no
benefit over placebo in terms of
abdominal pain
Alosetron,
ramosetron,
ondansetron
5-HT3 receptor
antagonists Effective High
Serious events with alosetron
included ischemic colitis and severe
constipation. Ramosetron and
ondansetron may be safer, although
constipation commoner with
active therapy.
Fewer RCTs of ramosetron and
ondansetron; ondansetron may
have no benefit over placebo in
terms of abdominal pain
Cholestyramine,
colestipol,
colesevelam
Bile acid
sequestrants Unknown Low Limited data No published RCTs
Rifaximin Non-absorbableantibiotic Effective Moderate
No increase in adverse events in a
meta-analysis of 5 RCTs
Only a modest benefit over
placebo in published RCTs
Lubiprostone Cl-C2 channelagonist Effective Moderate
Nausea commoner with active
therapy, occurring in 8% of patients
Only a modest benefit over
placebo in published RCTs
Linaclotide GC-C receptoragonist Effective High
Diarrhea commoner with active
therapy, occurring in 20% of pts None
Plecanatide GC-C receptoragonist Effective High
Diarrhea commoner with active
therapy, occurring in ~6% of pts None
Tenapanor NHE3 inhibitor Effective Moderate
Diarrhea commoner with active
therapy, occurring in 12% of pts Awaiting phase 2B/3 trials
Prucalopride 5-HT4 receptoragonist Effective high
Diarrhea, cramping, and
cardiovascular AEs with “old
generation” drugs in this class
Data available for tegaserod and
mosapride, not for “new
generation” drugs in this class:
prucalopride, naronapride,
velusetrag, YKP10811
Cl-C2 = chloride channel 2; GC-C = guanylate cyclase C; 5-HT = 5-hydroxy tryptamine; NHE = sodium-hydrogen
exchanger; RCT = randomized controlled trial; TSPO = translocator protein.
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The predominant site of action of the different classes of drugs is shown in Figure 1.
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Figure 1. Pharmacotherapy in Irritable Bowel Syndrome. 5-HT = 5-hydroxy tryptamine; 
GC-C-guanylate cyclase C; NHE = sodium-hydrogen exchanger; S2, 3, 4 = sacral nerves 2, 3 and 4. 
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2.1. Mechanism 
Antispasmodics inhibit the action of acetylcholine at muscarinic receptors, or via blockade of 
calcium channels, on gastrointestinal (GI) smooth muscle. Otilonium bromide targets not only  
L- and T-type calcium channels, but also muscarinic type 2 and tachykinin NK2 receptors, possibly 
contributing to its increased efficacy. As a class, antispasmodics have been used in the treatment of 
IBS for many years, on the basis that a subgroup of patients with IBS have abnormal contractility of 
GI smooth muscle, and altered GI transit, and that this contributes to pain and disturbances in bowel 
habit (reviewed in [11]).  
2.2. Efficacy 
2.2.1. Efficacy Focused on Systematic Reviews 
A 2005 Cochrane review concluded that there was weak evidence for the benefit of some 
antispasmodics for abdominal pain and global symptom relief, although it was unclear which 
individual classes were effective [12].  
A separate European systematic review in 2006 [13] identified nine placebo-controlled studies 
of antispasmodics in IBS with limitations identified due to lack of standardized diagnostic criteria, 
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2.1. echanism
Antispas odics inhibit the action of acetylcholine at uscarinic receptors, or via blockade of
calciu channels, on gastrointestinal (GI) smooth muscle. Otilonium bromide targets not only L-
and T-type calcium channels, but also muscarinic type 2 and tachykinin K2 receptors, possibly
contributing to its increased efficacy. As a class, antispas odics have been used in the treat ent of
IBS for any years, on the basis that a subgroup of patients ith IBS have abnor al contractility of
GI s ooth uscle, and altered GI transit, and that this contributes to pain and disturbances in bo el
habit (revie ed in [11]).
2.2. Efficacy
2.2.1. Efficacy Focused on Systematic Reviews
A 2005 Cochrane review concluded that there was weak evidence for the benefit of some
antispasmodics for abdominal pain and global symptom relief, although it was unclear which
individual classes were effective [12].
A separate European systematic review in 2006 [13] identified nine placebo-controlled studies of
antispasmodics in IBS with limitations identified due to lack of standardized diagnostic criteria, and
low to intermediate quality since they were performed before the development of the Rome criteria for
study design. Abdominal pain was significantly improved in 7 of 9 studies, bowel symptoms in 2 of 9,
and 4 of 9 studies reported global symptom severity improvement.
A 2008 meta-analysis identified 22 separate RCTs involving 1778 patients, studying 12 different
antispasmodic drugs [14]. Overall, as a class, antispasmodics were more effective than placebo, with a
relative risk of remaining symptomatic of 0.68 (95% CI 0.57 to 0.71), and a number-needed-to-treat
(NNT) of 5. Individual medications were efficacious when evaluated in subgroup analyses, with
estimated NNTs as follows: hyoscine 3.5 (3 trials, 426 patients), otilonium 4.5 (4 trials, 435 patients),
cimetropium 3 (3 trials, 158 patients), and pinaverium 3 (3 trials, 188 patients). However, significant
heterogeneity, moderate methodological quality, and possible publication bias reduce confidence in
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the estimation of efficacy; in addition, there was no report of efficacy according to IBS subtype. Of the
12 agents studied, the strongest data were for otilonium bromide and pinaverium. It is also important
to point out that most of the drugs studied in the trials included in this meta-analysis are licensed in
other countries including many countries in Europe and Asia, and are not licensed for the treatment of
IBS in the United States.
2.2.2. Efficacy Focused on Otilonium Bromide Trials
Clavé et al. randomized 356 patients with all subtypes of IBS to either 40 mg otilonium bromide
(OB) tid or placebo for 15 weeks [15]. Abdominal pain frequency score improvement by ≥1 pointwas
higher with otilonium (69%) versus placebo (56%, p = 0.02). This was measured on a 4-level rating
scale based on the number of pain episodes per week registered in the patient diary: 0 = 0 episode;
1 = 1–3 episodes, 2 = 4–7 episodes, 3 = 8 or more episodes. This effect was consistent across all IBS
subtypes. Otilonium also reduced the frequency of episodes of abdominal pain, abdominal bloating,
and improved global efficacy and probability of remaining relapse free during 10 weeks of follow up.
However, there was no significant difference in quality of life.
The efficacy of OB in IBS has been confirmed in four studies [14], including significant
improvement of abdominal pain and bloating severity with OB versus placebo [16] or reduction
in the number of pain episodes and severity of abdominal distention, improved well-being and global
assessment, but not in bowel symptoms [17]. A post-hoc analysis of symptom ratings found higher
response rates with OB for a wide range of symptoms [18].
2.2.3. Efficacy Focused on Pinaverium Trials
In an RCT of pinaverium conducted in 427 Chinese patients with IBS-D [19], 77.5% of patients
receiving pinaverium had either a ≥30% reduction from baseline in abdominal pain or a ≥50%
reduction in the number of days with at least one stool with a Bristol stool score≥6 at week 4, compared
with 33.5% with placebo (p < 0.001). The proportion of patients who achieved both endpoints at week 4,
was also higher with pinaverium (38.1% vs. 16.7%, p < 0.001). This is the only RCT of antispasmodic
drugs that utilizes an FDA-preferred endpoint for the treatment of IBS-D. However, these findings
need to be replicated in other ethnic groups and in studies of a longer duration.
2.3. Safety
Side effects were significantly more frequent with antispasmodics compared with placebo, the
commonest of which were dry mouth, dizziness, and blurred vision. Antispasmodics are generally
well tolerated, apart from anticholinergics which can cause atropine-like side effects, including
constipation [11].
3. Peppermint Oil
3.1. Mechanism
The major constituent of peppermint oil is menthol, which has antispasmodic properties. Menthol
inhibits smooth muscle contractility in the GI tract by blocking calcium influx, via L-type calcium
channels in the plasma membrane of smooth muscle cells [20,21]. Recent evidence has indicated that
this menthol-induced analgesia is mediated by activation of the temperature sensing ion channel,
TRPM8 [22]. This same receptor is expressed by nociceptive visceral afferents, where TRPM8 has
anti-nociceptive properties. One can thus anticipate that peppermint oil, if delivered efficiently to these
afferent nerve endings, may contribute to a better pain relief compared with standard antispasmodics.
3.2. Efficacy
In a meta-analysis from 2008 [14], peppermint oil was more effective than placebo in four trials,
containing 392 patients with IBS, with a relative risk of remaining symptomatic of 0.43 (95% CI 0.32 to
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0.59), and a NNT of 2.5. However, there was borderline heterogeneity between studies, and none of
the trials were of high-quality, which may have led to an over-estimate of its efficacy. In addition, the
effect of peppermint oil according to IBS subtype was not reported.
In a systematic review and meta-analysis of five randomized, controlled trials of an older
formulation of peppermint oil that included 197 patients on the active treatment arm and 195 on
placebo, the analysis favored peppermint oil (RR 2.23 (95% CI 1.78–2.81)) over placebo [23]. Peppermint
oil was significantly superior to placebo for global improvement of IBS symptoms (5 studies) and
improvement in abdominal pain (5 studies) [23]. Most of the clinical trials performed were however
small in size and, therefore, lacked sufficient statistical power to draw definite conclusions.
A novel formulation, designed for sustained release in the small intestine, is now available for
use in the US. In a 4-week trial of this formulation [24], comprising 72 patients with IBS-D or IBS-M,
there was a 40% reduction in symptom scores from baseline with peppermint oil, compared with a
24% reduction with placebo, although there was no superiority over placebo for total IBS symptom
score, but pain, bloating and urgency scores were reduced.
3.3. Safety
Peppermint oil can worsen gastroesophageal reflux symptoms and lead to heartburn, dry mouth,
belching, a peppermint taste, and a peppermint smell [11].
4. Antidepressants
4.1. Mechanism
There is a convincing rationale for the potential of antidepressants in IBS. For example, co-existent
psychological disorders are common among patients with IBS [25]; depression modifies the brain’s
response to painful stimuli [26]; antidepressants have beneficial effects in chronic painful disorders [27,28];
and they affect GI motility, with tricyclic antidepressants (TCAs) prolonging orocecal and whole gut
transit times, and selective serotonin re-uptake inhibitors (SSRIs) decreasing orocecal transit time [29].
It would therefore seem sensible to use TCAs in IBS-D, and SSRIs in IBS-C.
The mechanism of action of antidepressants in IBS remains uncertain, reduced activation of
pain centers in the anterior cingulate cortex during painful rectal distension in patients with IBS by
amitriptyline [30] suggests central effects on pain processing in addition to the effects on peripheral
mechanisms that may influence sensation (such as colonic compliance and visceral afferent function).
4.2. Efficacy
An updated systematic review and meta-analysis [31] identified 17 separate trials of
antidepressants with an overall beneficial effect on IBS symptoms: RR of remaining symptomatic
0.67 (95% CI 0.58 to 0.77), and an NNT of 4. However, only three of the RCTs were of high-quality—the
majority of trials were conducted in secondary or tertiary care, and there was evidence of heterogeneity
between studies and possible publication bias. In addition, two of the studies conducted in Iran, may
have been atypical with placebo response rate of 14% [32], or “complete” response to amitriptyline of
63% [33], which seems unusually high. Therefore, the estimated NNT of 4 for the antidepressant class
may be overestimated in this meta-analysis.
Antidepressant efficacy appears more convincing for TCAs, with an NNT of 4 and no
heterogeneity between the 11 studies, compared with SSRIs with an NNT of 4 but significant
heterogeneity between the seven trials. Seven RCTs (with 182 patients on antidepressants and
169 patients on placebo) reported the effect on abdominal pain, and the RR of abdominal pain
persisting was significantly lower compared with placebo (0.62; 95% CI 0.43 to 0.88); however, there
was considerable heterogeneity between studies (I2 = 72.4%). Effectiveness according to IBS subtype
has only been assessed in two RCTs to date [32,33]. It is unclear whether the efficacy of antidepressants
in IBS results from the treatment of co-existent depression. Three of the identified studies reported
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that there was no correlation between improvement in IBS symptoms and depression scores [34–36],
and a fourth trial reported that the benefit of desipramine (a TCA) was greater in non-depressed
individuals [37]. However, in an RCT by Ladabaum and colleagues [38], which excluded participants
with depression, there was no benefit of citalopram. A 12-week, open-label trial of the SSRI, duloxetine,
was conducted in 13 subjects with IBS and generalized anxiety disorder and showed improvement
in overall and severity scales of IBS as well as symptoms of anxiety and QOL [39]. Effectiveness
of antidepressants in relation to co-existent anxiety or other mental health conditions was seldom
assessed in the literature. For example, beneficial therapeutic effect of citalopram was independent
of effects on anxiety [35]. However, cognitive factors (sense of control over the condition, positive
relationship with therapist or study coordinator, confidence in treatment, improvement in maladaptive
cognitions, and quality of life during treatment) were all significant predictors of treatment response
to medical and psychological treatments (deipramine, education and cognitive behavioral therapy) in
functional bowel disorders, in contrast to demographic and other clinical variables which were not
predictive [40].
4.3. Safety
Side effects were significantly more common with TCAs, with the most frequent being drowsiness
and dry mouth. The meta-analysis by Ford et al. [30] documented that 31.3% of patients taking
antidepressants complained of adverse effects compared with 16.5% of those given placebo (RR = 1.63,
CI: 1.18–2.25). The number needed to harm was 9 (95% CI = 5–111).
Recent literature questions the safety of long-term use of antidepressants for non-psychiatric
indications because of a possible link with dementia with some classes of psychotropic drugs [41,42],
although causality has not been proven.
5. Drugs Acting on Opioid Receptors
5.1. Mechanism
Opioid receptor agonists slow GI and colonic transit, increase fluid absorption and reduce pain
sensation—a review of the overall effects on different regions of the gut appears elsewhere [43].
5.2. Efficacy
Loperamide and diphenoxylate, µ-opioid agonists, are anti-diarrheal agents that have been used
in IBS for many years [44]. However, this is based on limited evidence from rigorous RCTs. In one
small trial of 21 patients with IBS-D, loperamide appeared to be beneficial, in terms of improved stool
consistency, pain, and urgency [45]. In a second trial [46] conducted among 60 patients with either
functional diarrhea or IBS (only 21 patients had both abdominal pain and disordered bowel habit),
there was an improvement in stool frequency and consistency, as well as a reduction in the number of
days with pain. A third trial [47] demonstrated benefit of loperamide in an unselected cohort of IBS
patients with regard to stool frequency, stool consistency, and overall pain intensity, but with increased
abdominal pain during the night. A position statement for the management of IBS suggested that
there was insufficient evidence to recommend the use of loperamide [8], but the drug may be useful in
clinical practice in those with debilitating diarrhea or urgency.
Eluxadoline is a novel κ-, and µ-opioid receptor agonist and δ-opioid receptor antagonist. Three
large clinical trials, involving a total of over 3000 patients randomized to eluxadoline or placebo, have
demonstrated efficacy of eluxadoline in the relief of diarrhea or the composite endpoint of diarrhea
and pain over 12 weeks of treatment [48,49].
5.3. Safety
Adverse events with eluxadoline were chiefly nausea and headache, with rare cases of
pancreatitis and sphincter of Oddi spasm [48,49]. The drug is now licensed for the treatment
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of IBS-D in the United States but the FDA recommends that patients with a history of biliary
obstruction, cholecystectomy, pancreatitis, severe liver impairment, or severe constipation, and
patients who consume more than three alcoholic drinks per day should not be prescribed eluxadoline
(https://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm547907.htm).
6. 5-HT3 Receptor Antagonists
6.1. Mechanism
Serotonin, or 5-HT, is an important neurotransmitter in the brain and the enteric nervous system,
with 90% of the body’s total store of 5-HT contained within the intestinal enterochromaffin cells [50,51].
Patients with IBS-D have increased postprandial plasma 5-HT, while those with IBS-C have reduced
postprandial 5-HT levels [52]. Drugs that act on the 5-HT3 receptor, such as the antagonist alosetron [53],
are known to retard colonic tranist. 5-HT3 receptors are also important mediators of visceral pain [54].
6.2. Efficacy
Several meta-analyses of RCTs have shown that the drug is effective [55,56] with an NNT of 8 for
relief of abdominal pain and 4 for improvement in global symptoms. Alosetron is licensed for use in
women with severe IBS-D in the United States, but is regulated by an FDA prescribing program.
Ramosetron has been used in the treatment of IBS-D in both men and women, with response rates
respectively of 47% to 51%, compared with 27% to 32% with placebo (p < 0.001) [57,58], and it is now
licensed for use in patients with IBS-D in Japan.
In a cross-over clinical trial [59] of 120 patients with IBS-D, ondansetron had a significant effect
on stool consistency, as well as significant improvements in urgency, frequency of defecation, and
bloating, but again no effect on pain. Constipation occurred in 9% of patients on ondansetron.
6.3. Safety
As a drug class, 5-HT3 antagonists can induce constipation, although this is usually manageable
by titrating the dose; alosetron, but not other drugs in this class, is associated with ischemic colitis
(~1:800 treated patients) [60].
7. Experimental Approaches Using Visceral Analgesics
7.1. Histamine H1 Receptor Antagonist, Ebastine
Mechanism: Mast cells and their mediators, in particular histamine, serotonin and proteases, are
increasingly recognized as contributing to the pathogenesis of IBS [61]. Histamine is released by colonic
biopsies from patients with IBS and induces visceral hypersensitivity to colorectal distention in murine
models. Histamine sensitizes TRPV1 on neurons from murine dorsal root ganglia and on human
submucosal neurons in rectal biopsies via activation of H1 receptors [62]. Moreover, supernatant from
IBS biopsies sensitized murine DRG neurons, an effect also mediated via HRH1.
Efficacy: A clinical trial assessed 51 IBS patients who were treated with ebastine, a non-sedating
antagonist of histamine H1 receptors. Ebastine reduced visceral hypersensitivity and overall IBS
symptoms and abdominal pain in patients with IBS [62].
Safety: Headache, nausea, tiredness, and dry mouth are the most frequently reported adverse
events on ebastine treatment but their incidence was similar to placebo-treated patients with seasonal
and perennial rhinitis in 3 randomized, double-blind, multicenter clinical trials [63].
7.2. Neurokinin-2 Receptor Antagonist, Ibodutant
Mechanism: Neurokinins (NK, e.g., substance P) and NK2 receptors are abundantly expressed
in the GI tract and mediate smooth muscle in the gut. NK2 receptor activation is also involved in
stimulation of sensory nerves and activation of visceral reflexes.
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Efficacy: In a phase 2, dose-finding study, the highly selective NK2 antagonist ibodutant, which
has high oral bioavailability, improved pain severity in IBS-D, especially in those with a baseline
score > 1 [64]. A more recent multi-national, phase 2, randomized, double-blind, placebo-controlled
study in 559 patients showed a dose-dependent improvement in overall symptoms, abdominal pain
and stool pattern in IBS-D in females, but not in males; the best efficacy was observed with a 10 mg
dose [65].
Safety: The tolerability of the compound was reported to be excellent.
7.3. Selective Inhibitor of Translocator Protein TSPO
Mechanism: Translocator protein 18 kDa (TSPO) is a five-domain transmembrane protein that is
highly expressed in steroid-producing tissues, including the glial cells within the brain. ONO-2952 is a
novel and selective inhibitor of translocator protein 18 kDa that reduces stress-induced defecation and
visceral hyperalgesia in rat models.
Efficacy: In a proof of concept, multicenter study of 200 patients who were on treatment for
4 weeks, there was significant improvement with the 60 mg dose (but not the 20 mg dose) in worst
abdominal pain at week 3 [66]. There were also numerical, but not significant differences in abdominal
pain, stool consistency or stool frequency during the other weeks of treatment.
Safety: There were no clinically significant adverse events related to the study drug.
8. GABAergic Agents
Mechanism: GABAergic agents are α2δ ligands that generally bind potently to an auxiliary
protein associated with voltage-gated calcium channels, reducing depolarization-induced calcium
influx at nerve terminals. This reduces the release of several excitatory neurotransmitters, including
glutamate, noradrenaline, substance P, and calcitonin gene-related peptide (CGRP), which are involved
in pain mechanisms.
Efficacy: Forty patients with IBS-D were randomized for a 5-day period to treatment with
gabapentin, 300 mg/day and then 600 mg/day; rectal sensory thresholds were increased through
attenuating rectal sensitivity to distension and enhancing rectal compliance [67]. Pregabalin has been
tested in pharmacodynamic studies in healthy controls [68] and in patients with IBS, with significant
pharmacodynamic effects on rectal or colonic compliance and sensation thresholds or ratings [69].
A preliminary report of a randomized, controlled clinical trial of pregabalin, 225 mg, in 85 patients
with IBS reported lower average pain scores during weeks 9–12, and average symptom severity scores
were lower with pregabalin than placebo [70].
Safety: There are insufficient data in the preliminary report [70] to assess safety in IBS patients.
In the fibromyalgia literature, pregabalin, >300 mg dose, has been associated with somnolence,
dizziness, and >7% weight gain in an analysis of 5 trials with 3808 patients [71].
9. Bile Acid Sequestrants
About 25% of patients with IBS-D have evidence of bile acid malabsorption based on 75SeHCAT
scanning [72] or biochemical testing of serum or stool [73]. To date, there are no randomized, controlled
trials of BA sequestrants in IBS. In a single center open-label trial of 10 days of 1875 mg twice daily
colesevelam [74] in 12 patients with IBS-D and abnormal bile acid kinetics (increased fecal excretion
of bile acids and fasting serum C4 suggesting a compensatory increase in the hepatic synthesis of
bile acids), there was a reduction in stool consistency on the Bristol stool form scale. The number of
bowel movements per week correlated inversely with the total bile acid sequestered into the stool,
providing evidence for sequestration of bile acids being the mechanism for the observed improvement
in diarrhea. In another open-label study, Bajor and colleagues [75] treated 27 patients with IBS-D and a
75SeHCAT retention <20% with colestipol 1 g BID. After 8 weeks of treatment, there were significant
improvements in IBS symptom severity scores, stool frequency was reduced, and 15 (55.5%) of the
27 patients reported adequate relief of symptoms.
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10. Antibiotics
10.1. Mechanism
Some patients with IBS may have underlying small intestinal bacterial overgrowth (SIBO),
detected on hydrogen breath testing, and this can be reversed with non-absorbable antibiotics
such as rifaximin [76]. However, the use of hydrogen breath testing as a basis to treat SIBO is
controversial because of possible false positive results caused by rapid small bowel transit, unless
there is concomitant measurement of the arrival into the colon of radiolabel added to the substrate,
e.g., lactulose or glucose [77].
10.2. Efficacy
Rifaximin, a non-absorbable antibiotic, improved global symptoms and bloating in IBS in several
trials, including 2 phase III, randomized, placebo-controlled trials [78,79] comprising more than
1200 patients with non-constipated IBS. Rifaximin, 550 mg three times daily for 2 weeks, led to
significantly higher rates of adequate relief of global IBS symptoms and bloating with an NNT of
9–12.5; the effect on symptoms persisted out to 10 weeks post-treatment. However, stool consistency,
number of bowel movements, and urgency were not improved.
A meta-analysis of five randomized controlled trials of rifaximin [80], comprising 1803 patients,
reported similar efficacy with an NNT of 10 for improvement in global symptoms and bloating.
A further trial has been conducted [81], in which 2579 patients received open-label rifaximin, 550 mg
three times daily for 2 weeks. Among the 1074 patients who responded to treatment and were
successfully followed, 59.2% had a recurrence of symptoms at a median of 10 weeks (range 6 to
24 weeks) post-treatment. They were then randomized to up to two repeat courses of rifaximin,
550 mg three times daily for 2 weeks each, separated by 10 weeks, or placebo, in a double-blind
manner. Response rates were significantly higher with rifaximin after both the first and the second
repeat treatments, and with a difference in the percentage of responders of only 8% relative to placebo.
The FDA has approved the use of rifaximin for IBS-D patients with up to two repeat treatments in
case of recurrence of symptoms. A small randomized, controlled study [82] appraised the potential
mechanisms for the beneficial effect on symptoms in non-constipated IBS patients, and showed
acceleration of ascending colon emptying and overall colonic transit at 48 h, which is paradoxical
given the indication for this drug in the treatment of IBS-D. There were no differences from placebo in
terms of effects on permeability, stool microbiome, or stool bile acids.
10.3. Safety
Adverse event rates were similar to those associated with placebo and there were no
cases of Clostridium difficile [81]. Moreover, short-term, repeat treatment with rifaximin has no
apparent long-term effect on stool microbial susceptibility to rifaximin, rifampin, and non-rifamycin
antibiotics [83]. While long-term treatment with rifaximin is not the approved mode of administration
and its safety in patients with IBS has not been demonstrated, it is reassuring to note that long-term
use in patients with hepatic encephalopathy appears to be safe, and certainly safer than neomycin
treatment [84].
11. Intestinal Secretagogues
11.1. Chloride Channel-Related
Lubiprostone, a prostaglandin derivative, acts on CIC-2 chloride channels on the apical membrane
of the intestinal enterocyte. This leads to active chloride secretion with passive movement of sodium
ions and water into the lumen—GI transit is accelerated and stools become looser. The drug has been
studied at a dose of 8 mcg twice daily for 12 weeks in two large phase III trials including 1171 patients
with IBS-C [85]. In a pooled analysis from both RCTs, response rates (at least moderate relief of global
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symptoms for 2 out of the 3 months of therapy) were 17.9% with lubiprostone, compared with 10.1%
with placebo (p = 0.001). There were also improvements in abdominal pain scores, straining, and
stool consistency, but no significant effect on quality of life. Nausea was the commonest side effect,
experienced by 8% of patients.
Linaclotide is a minimally absorbed 14-amino acid peptide, which is a guanylate cyclase C
receptor agonist. This increases intra-cellular cyclic guanosine monophosphate (cGMP), secretion of
chloride and bicarbonate into the intestinal lumen, via the cystic fibrosis transmembrane regulator,
and sodium and water secretion. The increase in cGMP may also have effects on sensory afferent
neurons, leading to pain inhibition, an effect noted in the phase III clinical trials of the drug that were
conducted in chronic idiopathic constipation [86], where abdominal discomfort and bloating improved
significantly. In the two phase III trials of 290 mcg once daily conducted in IBS-C [87,88], response to
therapy (≥30% decrease in pain, and an increase of ≥1 complete spontaneous bowel movement per
week) was demonstrated in both trials and an NNT of 5 or 8 at 12 weeks. The main adverse event with
linaclotide was diarrhea, occurring in almost 20% of participants in both studies.
Plecanatide is a 16-amino acid peptide analog of uroguanylin. Uroguanylin is an endogenous
agonist that binds and activates guanylate cyclase-C (GC-C) receptors expressed in the epithelial lining
of the GI mucosa in a pH-sensitive manner [89]. In addition to published efficacy in patients with
chronic idiopathic constipation [90], there are preliminary reports of efficacy in patients with IBS-C [91].
Thus, two randomized trials involving 1135 patients (71.8% female) showed that plecanatide 3 mg
and 6 mg were associated with significant differences compared with placebo in terms of overall
responders (≥30% reduction in worst abdominal pain and an increase of ≥1 complete spontaneous
bowel movement from baseline, in the same week, for ≥50% of the 12 treatment weeks). Responder
rates in study one were: 3 mg, 30.2%, 6 mg, 29.5% compared with placebo 17.8%; and in study two:
3 mg, 21.5%, 6 mg, 24.0% compared with placebo, 14.2% (all comparisons with placebo p < 0.001).
Lubiprostone, linaclotide and plecanatide are all approved by the FDA for the treatment of chronic
idiopathic constipation—in addition, lubiprostone and linaclotide are also approved for IBS-C, and
plecanatide will be reviewed by the FDA for approval for the IBS-C indication in the first quarter
of 2018.
11.2. Sodium-Hydrogen Exchanger
Tenapanor is a small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger,
NHE3, which results in increased intraluminal sodium and water excretion. A phase 2 dose-response
study included 356 patients with IBS-C, of whom 305 completed the study [92]. Tenapanor, 50 mg
b.i.d., compared to placebo was associated with increased responder rate for complete spontaneous
bowel movement (CSBM) response (increase from baseline of ≥1 CSBM/week for ≥6/12 treatment
weeks), composite response (CSBM and abdominal pain), and individual abdominal symptoms (pain,
discomfort, bloating, cramping, and fullness). Diarrhea was the most frequent adverse event (50 mg
b.i.d., 11.2%). The 5 mg and 20 mg b.i.d. doses were not significantly different from placebo.
12. 5-HT4 Receptor Agonists
As a class, 5-HT4 receptor agonists have demonstrated efficacy in patients with IBS-C. In a
summary analysis of the major trials of tegaserod in patients with IBS in whom constipation was
the predominant symptom, Layer et al. evaluated major clinical trials of tegaserod, which involved
8948 IBS patients [93]. Tegaserod was an effective treatment for IBS-C, providing statistically significant
relief of overall and multiple individual IBS-C symptoms (abdominal pain/discomfort, bloating, and
constipation) in both placebo-controlled and open-label settings. Repeat treatments with tegaserod
were also shown to be effective, and tegaserod was associated with improvements in patients’ quality
of life and work productivity [93]. Adverse effects associated with tegaserod were diarrhea, cramping,
and cardiovascular AEs. Mosapride also accelerated gastric and small bowel transit time and improved
symptoms in patients with IBS-C in a pilot, 10-patient study [94]. However, in a 12-month study of
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69 patients, there were no significant improvements in overall IBS symptoms, specific symptoms (pain,
bloating, stool frequency or consistency) or quality of life with mosapride over placebo [95].
Tegaserod and cisapride were “old generation” drugs in this class, with cardiovascular liabilities
that have been resolved with newer medications in this class such as prucalopride, naronapride,
velusetrag, and YKP10811. However, these medications have been tested predominantly in chronic
idiopathic constipation where they have been shown to be efficacious based on systematic review [96]
or a single center combined pharmacodynamic and patient response study [97].
13. Conclusions
At the present time, the treatment of IBS remains focused on treating the patient’s predominant,
or most troublesome, symptom. However, the efficacy of most pharmacotherapies is modest,
high-quality evidence for some is sparse, and none have been shown to alter the long-term natural
history of the disorder. In the past, the treatment of IBS was an inexact science. However, therapies are
being developed that target some of the important pathophysiological mechanisms, and the methods
to plan and conduct high-quality, randomized, controlled trials are readily available. This augurs well
for impactful treatments in the future.
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